戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ions were significantly compromised in their oncogenicity.
2 itro; its cellular counterpart, c-P3k, lacks oncogenicity.
3 t palmitates make important contributions to oncogenicity.
4 ssociated with viral attenuation and loss of oncogenicity.
5 -terminus of v-Rel are required for its full oncogenicity.
6 hat inactivate lipid kinase activity abolish oncogenicity.
7 t of MEK did not significantly perturb R-Ras oncogenicity.
8 erefore an essential mediator of p3k-induced oncogenicity.
9 ic activities, but have dramatically reduced oncogenicity.
10 with the requirement of dcSAM production for oncogenicity.
11 ics, a metabolic route that is essential for oncogenicity.
12 ed tRNAs and altered cell cycle and inhibits oncogenicity.
13 o regulate their subcellular trafficking and oncogenicity.
14 ld-type KRAS, a potential basis for its weak oncogenicity.
15 C alterations strongly favored Ewing sarcoma oncogenicity.
16 reveals surprising diversity in Kras variant oncogenicity.
17 figure out their mechanisms and differential oncogenicity.
18 AKT modulates HH/GLI signal strength and its oncogenicity.
19 stoma pathogenicity that contributes to MYCN oncogenicity.
20 se enhanced GPCR pathway activation to favor oncogenicity.
21 d E2288K) domains of mTOR, and studied their oncogenicity.
22 ytes, which was necessary for ETV1-dependent oncogenicity.
23 rongly than c-Rel contributes to its greater oncogenicity.
24 ively activate kinase activity and increased oncogenicity.
25 -cell spread, for disease induction, and for oncogenicity.
26 2 months to identify genetic determinants of oncogenicity.
27 ts expression correlates with papillomavirus oncogenicity.
28 rexpression of p110alpha are correlated with oncogenicity.
29 , a mouse pathogen that is capable of potent oncogenicity.
30 ) that is thought to contribute to the viral oncogenicity.
31  intermediate kinase and hallmarks increased oncogenicity.
32 (BCR-ABL) mutants in regulating adhesion and oncogenicity.
33 gulation of the ErbB2-mediated signaling and oncogenicity.
34 pid tumor development, showing their driving oncogenicity.
35 EF) revealed the following prerequisites for oncogenicity: (1) removal of the N terminal phosphorylat
36        This mutation markedly enhances v-Jun oncogenicity [4] [5]; however, its transcriptional conse
37                 RB1BvIL-8DeltasmGFP retained oncogenicity, albeit at a greatly reduced level.
38  promising approaches to combat CDK5-induced oncogenicity, analogous to neurotoxicity triggered by nu
39 ve three types of classifications: germline, oncogenicity and clinical impact for somatic variants.
40 rgets, albeit through distinct mechanisms of oncogenicity and context-dependent contributions to canc
41                          However, KRAS(G12C) oncogenicity and downstream pathway activation were comp
42 en synthase kinase 3 activity for MLL fusion oncogenicity and identifies novel therapeutic targets fo
43                These effects may explain the oncogenicity and immunological perturbation of HCV infec
44     However, the molecular mechanism of ACTR oncogenicity and its function independent of nuclear rec
45                      Our results suggest the oncogenicity and potential targeting of HER2 missense mu
46 ng a role for Bin1 as a negative modifier of oncogenicity and progression in breast cancer.
47 DeltaEGFR makes a unique contribution to its oncogenicity and propose that this venue provides new ta
48 et, and Met contributes to EGFRvIII-mediated oncogenicity and resistance to treatment.
49 -FOXO1 expression, FGF8 upregulation rescued oncogenicity and simulated recurrence after PAX3-FOXO1-t
50 in c-Rel's cTAD1 and cTAD2 contribute to its oncogenicity and that of v-Rel.
51             On the basis of this model, both oncogenicity and tissue tropism appear to have evolved o
52 lly active mutants, to further examine their oncogenicity and tumorigenicity.
53 ide a biochemical explanation for vav family oncogenicity, and establish a new signaling model in whi
54  to advance studies on HBV pathogenicity and oncogenicity, and for discovery and preclinical validati
55 V1 genes with functions involving virulence, oncogenicity, and immune evasion.
56                   These mutant MDVs retained oncogenicity, and LBCLs have been established from the m
57 oreover, the immortalized cells exhibited no oncogenicity, and no up-regulation of c-Myc was detected
58 ferative capacity, hepatocellular functions, oncogenicity, and their in vivo maturation potential.
59 istinct mechanisms by which pluripotency and oncogenicity are established and regulated.
60 B-231 breast cancer cell line suppressed the oncogenicity as revealed by inhibition of the anchorage-
61 for normal regulation of kinase activity and oncogenicity as well as substrate selection.
62                      Most importantly, chick oncogenicity assays demonstrated that bic can cooperate
63 espite concerns for fetal teratogenicity and oncogenicity associated with diagnostic testing, and pot
64 gues of MDV1 oncoprotein MEQ, CxC chemokine, oncogenicity-associated phosphoprotein pp24, and conserv
65 e gene products include the oncoprotein MEQ, oncogenicity-associated phosphoproteins pp38 and pp24, a
66 he differences in host range, virulence, and oncogenicity between nonpathogenic HVT and highly pathog
67 enocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients hav
68 27 was not required for disease induction or oncogenicity but was required for chicken-to-chicken tra
69 n the 1990s, is critically involved in viral oncogenicity, but only a few of its host target genes ha
70 e identity of the gatekeeper residue impacts oncogenicity by altered P-loop phosphorylation.
71 osphorylation along with transactivation and oncogenicity by GOF p53, indicating that GOF p53 exploit
72 iated by or dependent on TAD is required for oncogenicity by GOF p53.
73 bitor, LY3009120, could suppress CRAF-fusion oncogenicity by inhibiting dimer-mediated signaling.
74                     We investigate potential oncogenicity by interrogating cancer pathways affected b
75 e further dissection of the requirements for oncogenicity by the E4orf6 protein.
76  localization signal in v-Rel did not affect oncogenicity by v-Rel.
77 essing pool cells exhibited greatly enhanced oncogenicity compared with control pool cells.
78 cated or mutant isoforms that show increased oncogenicity compared with the wild-type receptor are fo
79  those showing minimal DNA binding, retained oncogenicity for CEF.
80 roduced a deep learning framework to predict oncogenicity for these variants using both functional an
81 rminal repeat, which may explain the loss of oncogenicity for this strain.
82 gical controls were comparable, the measured oncogenicity from exactly one alpha particle was signifi
83 ls resulted in accelerated EGFRvIII-mediated oncogenicity in an orthotopic mouse model.
84 tively blocked ErbB signaling and attenuated oncogenicity in breast cancer cells, yet had little effe
85 to the mechanisms that may contribute to 2HG oncogenicity in glioma and acute myeloid leukaemia progr
86 ate the cell cycle through E2F underlies its oncogenicity in human cancers.
87 dition to amplifications, could activate its oncogenicity in human lymphomas.
88 wed that CNNM binding was sufficient for PRL oncogenicity in one model of metastasis, but left unreso
89  RSK3-mediated phosphorylation with enhanced oncogenicity in promoting colon cancer growth.
90 s that cofactors could be required for viral oncogenicity in some cases.
91 1 SH3 domain is essential for LASP1-mediated oncogenicity in these cells.
92                To determine whether the AIB1 oncogenicity in this model depended on its function as a
93 und GLPG1690 suppressed TSC2-loss associated oncogenicity in vitro and in vivo and induced apoptosis
94 usion proteins and tested their activity and oncogenicity in vitro and in vivo in transgenic mice (TM
95 efractory to nuclear export display heighten oncogenicity in vitro compared with WT D1, we generated
96 et no experimental model demonstrating their oncogenicity in vivo.
97 alized rodent fibroblasts in vitro and their oncogenicity in vivo.
98 tric epithelial cell polarity to achieve its oncogenicity is not fully understood.
99      This represents an example of how acute oncogenicity is promoted by collaborations between cell
100  the limited set of genes associated with MD oncogenicity, MDV-miR-M4, a highly expressed viral ortho
101 factor that may contribute to the dissimilar oncogenicities of Ad and HPV.
102 blasts, suggesting a correlation between the oncogenicity of Akt and phosphorylation of S6K and 4E-BP
103 ults in suppression of kinase activation and oncogenicity of associated p185neu-activated receptors.
104 l protein with p40 did not increase the weak oncogenicity of c-Rel.
105 ession of Atoh1 in primary GNPs enhances the oncogenicity of cells overexpressing Gli1 by almost thre
106  of either AKT or the HER family reduced the oncogenicity of driver mutations.
107                             We evaluated the oncogenicity of eight kinase inhibitor-resistant BCR-ABL
108 tively, these data provide evidence that the oncogenicity of ERG is mediated, in part, by competition
109 lts underscore the qualitative difference in oncogenicity of GLI1 and Gli2 when overexpressed in skin
110 the structure of the AdE1A spacer region and oncogenicity of HAdVs, the structures of synthetic pepti
111 on of this domain substantially enhanced the oncogenicity of HOXB4, inducing acute leukemia in mice.
112            In light of recent studies on the oncogenicity of JCV and the transforming ability of the
113                                          The oncogenicity of Jun probably results from transcriptiona
114  relevance of noncanonical functions for the oncogenicity of KV10.1, which need to be considered when
115 ting that this pathway may contribute to the oncogenicity of LMP1 through its ability to promote cell
116 tem cell biology and for the analysis of the oncogenicity of LRP receptors that are often overexpress
117 ein-protein interactions is critical for the oncogenicity of many hotspot mutations.
118 ntifying oncogenic driver mutations, but the oncogenicity of many variants identified in tumours rema
119 -encoded protein (Meq), is essential for the oncogenicity of MDV.
120                It has been reported that the oncogenicity of Meq is associated with its interaction w
121  that this signaling connection sustains the oncogenicity of Merlin-deficient tumor cells.
122  a Dicer1 mutant mouse model establishes the oncogenicity of missense mutations in the DICER1 RNase I
123 s (CR2 and CR3) of AFX are required for full oncogenicity of MLL-AFX and also endow it with the poten
124 missive cellular environment is required for oncogenicity of Mll-associated translocations and Mll fu
125 llular environment is therefore required for oncogenicity of Mll-associated translocations since the
126 as protein and PI 3-kinase are causal in the oncogenicity of mutant Ras proteins.
127 nd functional analysis provides insight into oncogenicity of mutations in RbN and identifies a unique
128                                          The oncogenicity of Myc stems from its ability to regulate e
129 hese results support the conclusion that the oncogenicity of P3k depends on constitutive lipid kinase
130                                  The in vivo oncogenicity of PIK3CA mutants in an avian species stron
131 experiments demonstrated that CHD6 regulates oncogenicity of prostate cancer cells and tumor developm
132           Our results demonstrate the direct oncogenicity of Rac1 and ROS and their contribution to a
133                Our findings suggest that the oncogenicity of RARalpha-fusion proteins results from th
134 educed level of transactivation enhances the oncogenicity of REL; (3) that REL shuttles from the cyto
135 is work demonstrates that ceRNAs mediate the oncogenicity of somatic CNAs.
136                                          The oncogenicity of Sox3 is correlated with nuclear localiza
137 ptibility to AAP1 regulation correlates with oncogenicity of the activated forms of c-ABL.
138  of activity per se was not the cause of the oncogenicity of the D463H mutant.
139 molecule targeting the GBD might inhibit the oncogenicity of the mutant CALR.
140    Finally, our simulations suggest that the oncogenicity of the R335L mutation may be due to a reduc
141 d in recent years, consistent with the acute oncogenicity of the viral oncoprotein v-Rel in animal mo
142                               Therefore, the oncogenicity of therapeutically valuable patient-specifi
143                      We demonstrate that the oncogenicity of these mutant p110alpha proteins is depen
144 1 into exosomes is associated with increased oncogenicity of these secreted vesicles.
145 ts that this pathway contributes both to the oncogenicity of this molecule and its role in the establ
146                                          The oncogenicity of this virus is reflected in vitro by its
147               These experiments document the oncogenicity of transactivating LEF-1 and show that the
148 en selected for their ability to enhance the oncogenicity of v-Rel by increasing its ability to activ
149                                   The potent oncogenicity of v-Rel is the consequence of a number of
150  amino acids into v-Rel markedly reduced the oncogenicity of v-Rel.
151                   Brk also conferred in vivo oncogenicity on the BaF3 cells.
152  Additionally, we explore the origins of the oncogenicity/oncolyticity of certain pathogens and the r
153  intact gD homolog gene is not essential for oncogenicity or horizontal transmission of MDV.
154 ine with minimum concerns of tumorigenicity, oncogenicity, or adventitious agents.
155                                         RBP2 oncogenicity relied on its demethylase and DNA-binding a
156 cell cycle-independent mechanisms behind its oncogenicity remain ambiguous.
157  However, mechanisms underlying HBx-mediated oncogenicity remain unclear.
158  critical determinants of their differential oncogenicity reside in their divergent transactivation d
159 hare covalent dimerization as a mechanism of oncogenicity, suggesting the need for novel inhibitors t
160 active PTEN mutant (G129R) to suppress MSP58 oncogenicity, support the view that the C-terminal regio
161 udy provides some insight into the potential oncogenicity that may arise via cellular reprogramming,
162 mmunogenicity of mesenchymal stem cells, and oncogenicity) that have been addressed and will be follo
163  this loss of function, mutant p53 can drive oncogenicity through a dominant-negative effect by formi
164 e therefore conclude that AIB1 can exert its oncogenicity through tissue-specific estrogen-dependent
165  specifically at three positions that confer oncogenicity to Ras (12, 59, and 61).
166 ly, autophosphorylation at this site confers oncogenicity to this receptor.
167 s regulatory connection contributes to Myb's oncogenicity, we expressed a dominant negative Myb in th
168  Similar to CtBP's role in attenuating E1A's oncogenicity, we propose that dCtBP can interfere with c
169 l-xL and Bcl-2 significantly increased their oncogenicity, whereas other NF-kappaB-regulated death in
170 in the switch-II domain is required for KRAS oncogenicity, which could be exploited for developing in

 
Page Top